Skip to main content

Symtuza FDA Approval History

FDA Approved: Yes (First approved July 17, 2018)
Brand name: Symtuza
Generic name: cobicistat, darunavir, emtricitabine and tenofovir alafenamide
Dosage form: Tablets
Company: Johnson & Johnson Innovative Medicine
Treatment for: HIV Infection

Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) is a once daily, single-tablet regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically suppressed adults.

Development timeline for Symtuza

DateArticle
Jul 17, 2018Approval FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
Sep 25, 2017Janssen Submits NDA to U.S. FDA for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1

See also

Symtuza (cobicistat, darunavir, emtricitabine and tenofovir alafenamide) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer